This phase II trial studies the effects of trastuzumab deruxtecan in treating patients with HER2 positive osteosarcoma that is newly diagnosed or has come back (recurrent). Trastuzumab deruxtecan is a monoclonal antibody, called trastuzumab, linked to a chemotherapy drug called deruxtecan. Trastuzumab attaches to HER2 positive cancer cells in a targeted way and delivers deruxtecan to kill them. THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.  Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:IU Clinical Trials Office Email: iutrials@iu.edu Phone: (317) 278-5632

Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.Interested in participating? For more information about this research study or other cancer-related clinical trials at Indiana University Simon Comprehensive Cancer Center (IUSCCC), please contact the IU Clinical Trials Office at:Email: iutrials@iu.edu Phone: (317) 278-5632

Hospital at home is being implemented as an alternative post-operative care delivery system for selected colorectal patients who meet medical and geographic criteria to be discharged directly home to the hospital at home program after surgery. The purpose of this study is to gain insight into the patient experience of hospital at home by conducting a mixed-methods study with surveys and semi-structured interviews to collect patient-reported outcomes of the experience. Also, to understand the provider experience we will conduct focus groups of providers involved in the program.THIS STUDY IS ENROLLING BY INVITATION ONLY - Patients are identified for the HaH program initially by the colorectal surgery team, who determine they are potential appropriate candidates undergoing the approved procedures. At this time their information is given to the HaH team as a referral for enrollment in the program and they determine if the patient is eligible to proceed based on co-morbidities, medical needs, and geographic location. If the patient is successfully enrolled in and participates in the HaH program after surgery, they are eligible for participation in the study. Participants in the focus group portion of the study will be determined to be eligible if they are members of the colorectal surgery team (surgeons, APPs, clinic nurses) or take care of colorectal surgery patients in the HaH program (HaH nurses, team members).

The purpose of this study is to gain a better understanding of the structure of the vitreous (the clear gel that fills the space between the lens and the retina) and the reason behind the failure of most retinal detachment surgeries. There is a 10% failure rate for primary retinal detachment surgery with 75% of those failures due to proliferative vitreoretinopathy also known are PVR. PVR is when membranes develop on top or under the retina. This membrane contracts and pulls at the retina causing secondary retinal detachment. This study is to identify the mechanism involving in formation of PVR. We are looking into the immune cell role in PVR formation and different in chemokine (small proteins involving in attracting immune cells) levels in the vitreous of patients with vitreoretinal pathology.THIS STUDY IS ENROLLING BY INVITATION ONLY - Patients will be recruited through eye clinics at specified sites in the protocol. Those individuals who need vitreoretinal surgeries will be identified by their treating physician and recruited in the study by the study team during the same clinic encounter for surgical scheduling.  

The purpose of this trial is to measure depressive symptoms following treatment with ALTO-207 compared with placebo in participants with TRD. 

The purpose of this study is to identify a better tool for diagnosing patients with urinary infections and kidney stones when they come to the emergency room with abdominal or back pain (renal colic). This tool will help practitioners identify more easily if patients have a urinary infection along with a kidney stone. the primary objective is to predict accuracy of a new 4-point risk score which predicts a clinically significant UTI in patients presenting to the emergency department with obstructing kidney stones and concern for UTI requiring a ureteric stent or nephrostomy tube.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential participants with 1 or more obstructive urinary tract calculi on CT scan in the emergency department and urology consultation for consideration of decompression (nephrostomy tube or ureteric stent) will be approached in the ER by the study team about study participation.